The DDI Advisory Board, which bolsters our strategic direction, consists of internationally recognized experts with proven track records in pharmaceutical drug discovery, development and commercialization.
- Holds quarterly and ad hoc meetings as needed
- Engages and interacts frequently with the DDI team
- Conducts scientific reviews of proposed and ongoing projects
- Manages pipeline
- Offers guidance for business development and licensing
Timothy R. Wright, BS – Chair of Advisory Board
Mr. Wright founded the DDI in 2011. He is currently CEO of M2Gen, a Moffitt Cancer Center subsidiary. Mr. Wright has more than 30 years of experience in the pharma and biotech industries. He was previously executive vice president (VP) of Business Development, Strategy and Innovation at Teva Pharmaceuticals, president of Covidien Pharmaceuticals, president of Global Operations of Elan Pharmaceuticals, and senior VP (SVP) at DuPont Merck Pharmaceutical.
John Byrd, MD
Dr. Byrd is Distinguished University Professor of Medicine. He is the co-leader of the leukemia research program and manages the Experimental Hematology Laboratory. He holds the D. Warren Brown Endowed Chair of Leukemia Research at the at The Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). He is a physician scientist focused on immune and molecular pharmacology and clinically on developing new treatments for acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). He has more than 400 publications related to his work. Dr. Byrd has participated in the comprehensive development of five drugs that ultimately have been FDA approved for CLL and AML.
David Carbone, MD, PhD
Dr. Carbone is professor of Internal Medicine, director of the OSUCCC – James Thoracic Oncology Center and the Barbara J. Bonner Chair in Lung Cancer Research. He is a world-renowned lung cancer expert with over 200 peer-reviewed publications.
Pat Confalone, PhD
Dr. Confalone is R&D consultant at Confalone Consulting, LLC. He has over 46 years of R&D experience and is an expert in medicinal chemistry, process R&D, and preclinical development. He was previously VP at DuPont, VP at Bristol-Myers Squibb, SVP at DuPont Merck Pharmaceuticals and Chairman of the Board of the American Chemical Society.
Arthur Morelli, BA
Mr. Morelli is CEO of Arthur F. Morelli and Associates Consulting. He is a pharmaceutical industry professional with over 35 years of leadership experience as senior director at DuPont Pharma; VP, Elan Biopharmaceuticals; VP, Cardinal Health; EVP, Solstice Neurosciences Inc.; and VP, Covidien/Mallinckrodt Pharmaceuticals. Art is currently the Chief Business Officer of Enlyton, Ltd, a nascent oncology company based in Columbus, OH.
Briggs Morrison, MD
Dr. Morrison is CEO of Syndax Pharmaceuticals and a Managing Director at MPM Capital. He brings over 30 years of pharmaceutical research and development experience. Prior to joining Syndax and MPM, he served as Chief Medical Officer and Executive VP for Global Medicines Development at AstraZeneca and head of clinical development at Pfizer. He also served as Chairman of the Board of Transcelerate, and industry-funded company charged with improving operational aspects of clinical trials.
Herbert Neuman, MD, MBA
Dr. Neuman is president, R3xperts Consulting, a boutique pharmaceutical industry consultancy. He is board certified in Internal Medicine and has over 15 years of experience in the Pharma industry. He was previously VP of global regulatory affairs at Mallinckrodt and chief medical officer and VP medical affairs at Covidien Pharma.
Bobby Sandage, PhD
Dr. Sandage is President and CEO of Euclises, General Partner in Cultivation Capital Life Sciences Fund II. He brings over 35 years of pharmaceutical research and development experience. He was formerly President and CEO of Coronado Biosciences, head of oncology program at Covidien Pharmaceuticals, EVP and chief scientific officer at Indevus Pharmaceuticals, and has held senior drug development positions at DuPont Merck. Additionally, he remains an active board member of Mateon (MATN), Immunophotonics and Tensive Controls.
Robert Stein, MD, PhD
Dr. Stein is Senior Advisor and former president, R&D at Agenus Inc. He brings over 35 years of experience in innovation and leadership in the Pharma and Biotech industries. Previously, he was executive vice president (EVP) of research & development for DuPont Merck Pharmaceuticals, president of R&D and chief scientific officer (CSO) for Incyte Pharmaceuticals, president of Roche Palo Alto, and CEO of KineMed.
For more information, contact the DDI at firstname.lastname@example.org.